Brumfitt W, Smith G W, Hamilton-Miller J M, Bax R
J Antimicrob Chemother. 1985 Dec;16(6):781-8. doi: 10.1093/jac/16.6.781.
Ninety-seven patients with a history of recurrent bacteriuria were treated with cinoxacin in a dosage of either 250 mg (48 patients) or 500 mg (49 patients) 12-hourly for seven days. Both regimens had a success rate in excess of 85% one week after the end of treatment, and only 15% of the patients rendered abacteriuric had relapsed four weeks later. Both dosage regimens of cinoxacin were very well tolerated. Our results show that in patients with recurrent urinary infections the conventional dosage of cinoxacin (500 mg) can be reduced to 250 mg 12-hourly without any loss of efficacy. Consequently patients seen in family practice with uncomplicated lower tract urinary infection can confidently be expected to respond equally well to a dose of 250 mg 12-hourly with the obvious advantages of less toxicity, less chance of producing resistance in the bowel flora and lower cost.
97例有复发性菌尿病史的患者接受了西诺沙星治疗,剂量为250毫克(48例患者)或500毫克(49例患者),每12小时一次,共7天。两种治疗方案在治疗结束后一周的成功率均超过85%,且只有15%的患者在四周后复发。西诺沙星的两种剂量方案耐受性都很好。我们的结果表明,对于复发性尿路感染患者,常规剂量的西诺沙星(500毫克)可减至每12小时250毫克,而不会降低疗效。因此,可以预期,在家庭医疗中遇到的单纯性下尿路尿路感染患者,每12小时服用250毫克剂量的药物也会有同样良好的反应,且具有毒性更低、肠道菌群产生耐药性的可能性更小以及成本更低等明显优势。